Autologous dinitrophenyl-modified tumor cell antigens (L-Vax antigens)

Tumor cell antigens presented by L-Vax are a collection of autologous tumor-associated antigens (TAAs) and tumor-specific antigens (TSAs) derived from a patient's own cancer cells, primarily in the context of non-small cell lung cancer (NSCLC) or acute myeloid leukemia (AML) (AVAX Technologies SEC Filing, 2006; NIH Clinical Trials, 2015). These antigens are modified through a process known as haptenization, where the chemical hapten dinitrophenyl (DNP) is conjugated to the surface of the tumor cells to enhance their immunogenicity (AVAX Technologies SEC Filing, 2006). The primary biological function of this target is to serve as an immunogenic substrate that triggers a systemic, cell-mediated immune response against the patient's residual tumor cells (AVAX Technologies SEC Filing, 2006; NIH Clinical Trials, 2015). When administered as the L-Vax vaccine, these modified antigens are processed by antigen-presenting cells and presented to T cells, leading to the activation of cytotoxic T lymphocytes (CTLs) and helper T cells (AVAX Technologies SEC Filing, 2006; ResearchGate, 2023). This approach is designed to overcome the immune tolerance often associated with cancer by presenting the full antigenic fingerprint of the tumor in a highly inflammatory context (AVAX Technologies SEC Filing, 2006; NIH Clinical Trials, 2015). Clinical development of L-Vax has focused on its use as an adjuvant therapy to prevent disease recurrence following surgical resection or chemotherapy (AVAX Technologies SEC Filing, 2006; NIH Clinical Trials, 2015). The efficacy of the immune response against these antigens is often monitored using delayed-type hypersensitivity (DTH) skin tests as a biomarker for T-cell activation (AVAX Technologies SEC Filing, 2006).

Other names

DNP-modified tumor antigensHapten-modified tumor antigensAutologous tumor-associated antigensL-Vax target antigensAC Vaccine antigens

Induction of a systemic immune response against autologous tumor antigens through haptenization (DNP modification), which enhances the visibility of tumor-associated antigens to the immune system, primarily via T-cell activation and delayed-type hypersensitivity (DTH) reactions.